

FULLY FUNDED CLINICAL TRIAL FOR MELANOMA, OSTEOSARCOMA, SOFT TISSUE SARCOMA, OR SQUAMOUS CELL CARCINOMA

Veterinary Cancer Group (Culver City location) in cooperation with Animal Clinical Investigations is currently enrolling dogs for a nationwide clinical trial to evaluate a novel cancer treatment for measurable melanoma, osteosarcoma, soft tissue sarcoma, or squamous cell carcinoma. The goal of this therapy is to specifically target the tumor and induce an inflammatory response. The proposed benefit of such a response is to shrink existing tumors and reduce or eliminate microscopic cancer cells that may not be visible by standard (or any) means. The purpose of this study is to assess the safety and potential effectiveness of this therapeutic agent in dogs.

Clinical study details

The study sponsor will pay for the study agent, diagnostic tests and follow-up evaluations. In the event that side effects are noted and attributed to the therapeutic agent, the study will pay for medical management of the side effects.

Therapeutic agent background

The therapeutic agent is a modified anaerobic bacterium. In previous trials, it has been shown to target the necrotic center of malignant tumors, leading to tumor regression or stable disease in many of the small mammals tested. Common side effects include fever, nausea and inflammation.

Trial eligibility

Dogs are eligible if they meet the following inclusion criteria:

- Histologic or cytologic diagnosis of cancer (biopsy or needle aspirate)
- There is at least 1 tumor (melanoma, osteosarcoma, soft tissue sarcoma, or squamous cell carcinoma) which can be measured (minimum 1 cm in diameter)
- Generally feeling well (i.e. eating, drinking, ambulating on their own, etc.)
- No evidence of an active bacterial infection requiring antibiotics (other than topical medications) in the past 7 days
- No anti-cancer therapy within the past 21 days. This includes chemotherapy, radiation therapy, prednisone (or other forms of corticosteroids), and immunotherapy
- NSAID therapy is allowed if this has been a historical medication
- No tumors where abscess (infection) would result in major symptoms
- Performance score of 0 or 1 (normal activity or decreased activity from pre disease status)
- Dogs must be available for follow up visits for a minimum of 2 months



2887 Edinger Avenue • Tustin, California 92780 • 949.552.8274 *phone*
9599 Jefferson Boulevard • Culver City, California 90232 • 310.558.6120 *phone*
5040 Convoy Street, Suite B • San Diego, California 92111 • 619.414.5056 *phone*
20051 Ventura Boulevard, Suite D • Woodland Hills, California 91364 • 818.888.6882 *phone*
www.vetcancergroup.com • info@vetcancergroup.com